A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Natacyn Warnings, Precautions, Pregnancy, Nursing, Abuse - Natamycin
Natacyn Warnings, Precautions, Pregnancy, Nursing, Abuse - Natamycin
WARNINGS
No Information Provided.
PRECAUTIONS
General. For topical eye use
only NOT FOR INJECTION. Failure of improvement of keratitis following 7-10
days of administration of the drug suggests that the infection may be caused
by a microorganism not susceptible to natamycin.
Continuation of therapy should be based on clinical re-evaluation and additional
laboratory studies.
Adherence of the suspension to areas of epithelial ulceration or retention
of the suspension in the fornices occurs regularly. There have only been a limited
number of cases in which natamycin has been used; therefore, it is possible
that adverse reactions of which we have no knowledge at present may occur. For
this reason, patients on this drug should be monitored at least twice weekly.
Should suspicion of drug toxicity occur, the drug should be discontinued.
Information for Patients : Do not touch dropper tip
to any surface, as this may contaminate the suspension.
Carcinogenesis, Mutagenesis, Impairment of Fertility: There
have been no long term studies done using natamycin in animals to evaluate carcinogenesis,
mutagenesis, or impairment of fertility.
Pregnancy: Pregnancy Category C. Animal reproduction studies
have not been conducted with natamycin. It is also not known whether natamycin
can cause fetal harm when administered to a pregnant woman or can affect reproduction
capacity. NATACYN (natamycin ophthalmic suspension, USP) 5% should be given
to a pregnant woman only if clearly needed.
Nursing Mothers: It is not known whether these drugs are
excreted in human milk. Because many drugs are excreted in human milk, caution
should be exercised when natamycin is administered to a nursing woman.
Pediatric Use: Safety and effectiveness in pediatric patients
have not been establised.
top
